Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

Am J Hematol. 2012 Jul;87(7):732-3. doi: 10.1002/ajh.23219. Epub 2012 May 24.

Abstract

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Deferiprone
  • Deferoxamine / administration & dosage
  • Deferoxamine / therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / drug effects*
  • Heart Ventricles / physiopathology*
  • Humans
  • Iron Chelating Agents / administration & dosage
  • Iron Chelating Agents / adverse effects*
  • Male
  • Models, Biological
  • Pyridones / administration & dosage
  • Pyridones / therapeutic use*
  • Retrospective Studies
  • Stroke Volume / drug effects
  • Time Factors
  • Ultrasonography
  • beta-Thalassemia / drug therapy*
  • beta-Thalassemia / physiopathology*

Substances

  • Iron Chelating Agents
  • Pyridones
  • Deferiprone
  • Deferoxamine